About efgartigimod alfa fcab
Neonatal Fc receptor blocker
Used for
- Treats generalized myasthenia gravis in adults with acetylcholine receptor antibodies.
Usual adult dose
10 mg/kg by intravenous infusion weekly for four weeks; cycles may be repeated according to response.
Common side effects
- Respiratory or urinary infections
- Headache
- Injection-site reactions
- Low white blood cell count
Important warnings
- May increase infection risk; treat active infections before starting.
- Vaccinations may be less effective during treatment; avoid live vaccines.
- Monitor for allergic reactions during and after infusion.
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential risk.
Breastfeeding
It is unknown whether efgartigimod passes into human milk; effects on infants are unknown.
Interactions
- May reduce the effectiveness of medicines that bind neonatal Fc receptors, including immunoglobulin products and some monoclonal antibodies.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.